Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02226315 · ClinicalTrials.gov registry record
Clinical Performance of the MaterniT21 PLUS LDT in Multiple Gestation Pregnancies
A clinical trial, sponsored by Sequenom.
- Terminated
- Registry status
- 50
- Enrollment target
NCT02226315 is a clinical trial that was terminated before completion, run by Sequenom. The registered enrollment target is 50 participants.
The verdict
NCT02226315 was terminated before completion, sponsored by Sequenom.
- TERMINATED
- Registry status
- 50 participants
- Enrollment target
Study Summary
This study will evaluate the clinical performance of massively parallel sequencing (MPS) using the MaterniT21 PLUS LDT in the detection of fetal aneuploidy in circulating cfDNA extracted from a maternal blood sample obtained from women pregnant with a multiple gestation who were at increased risk for fetal aneuploidy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02226315
The ClinicalTrials.gov registry entry for NCT02226315 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sequenom, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02226315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02226315 about?
NCT02226315 is a clinical study titled "Clinical Performance of the MaterniT21 PLUS LDT in Multiple Gestation Pregnancies". This study will evaluate the clinical performance of massively parallel sequencing (MPS) using the MaterniT21 PLUS LDT in the detection of fetal aneuploidy in circulating cfDNA extracted from a maternal blood sample obtained from women pregnant with a multiple gestation who were at increased risk fo...
What is the current status of trial NCT02226315?
This trial is currently terminated. The enrollment target is 50 participants. The study started on 2014-08. Estimated completion is 2015-09.
Who is sponsoring clinical trial NCT02226315?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.